Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth
Update your Virtual Booth on PharmaCompass, ask us
About
Not Confirmed
Not Confirmed
26-28 August, 2025
Not Confirmed
Not Confirmed
12-14 August, 2025
Not Confirmed
Not Confirmed
17-21 August, 2025
List your booth number for exhibitions, ask us
CONTACT DETAILS
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Events
Webinars & Exhibitions
Industry Trade Show
Not Confirmed
26-28 August, 2025
Industry Trade Show
Not Confirmed
12-14 August, 2025
Industry Trade Show
Not Confirmed
17-21 August, 2025
Digital content
INTERVIEW #SpeakPharma
[Sponsored by another company]https://www.pharmacompass.com/speak-pharma/50-years-of-innovation-mikart-s-legacy-and-what-s-next-in-cdmo-excellence
VLOG #PharmaReel
[Sponsored by another company]DATA COMPILATION #PharmaFlow
[Sponsored by another company]https://www.pharmacompass.com/radio-compass-blog/cdmo-activity-tracker-veranova-carbogen-lead-adc-investments-axplora-polfa-tarchomin-famar-expand-european-footprint
28 Jul 2025
// BUSINESSWIRE
https://www.businesswire.com/news/home/20250728226286/en/Exelixis-Announces-Second-Quarter-2025-Financial-Results-and-Provides-Corporate-Update
24 Jul 2025
// BUSINESSWIRE
https://www.businesswire.com/news/home/20250724850513/en/Exelixis-Partner-Ipsen-Receives-European-Commission-Approval-for-CABOMETYX-cabozantinib-for-Patients-with-Previously-Treated-Advanced-Neuroendocrine-Tumors
14 Jul 2025
// BUSINESSWIRE
https://www.businesswire.com/news/home/20250714485475/en/Exelixis-to-Release-Second-Quarter-2025-Financial-Results-on-Monday-July-28-2025
22 Jun 2025
// BUSINESSWIRE
https://www.businesswire.com/news/home/20250622399674/en/Exelixis-Announces-Zanzalintinib-in-Combination-with-an-Immune-Checkpoint-Inhibitor-Improved-Overall-Survival-in-STELLAR-303-Phase-3-Pivotal-Trial-in-Patients-with-Metastatic-Colorectal-Cancer
22 May 2025
// BUSINESSWIRE
https://www.businesswire.com/news/home/20250522412302/en/Exelixis-Announces-Encouraging-Results-from-Phase-1b2-STELLAR-002-Trial-Evaluating-Zanzalintinib-in-Combination-with-Immune-Checkpoint-Inhibitors-in-Advanced-Kidney-Cancer-at-ASCO-2025
22 May 2025
// BUSINESSWIRE
https://www.businesswire.com/news/home/20250522858444/en/Exelixis-to-Webcast-Fireside-Chats-as-Part-of-Upcoming-Investor-Conferences-in-May-and-June
ABOUT THIS PAGE